Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01E PROTEIN KINASE INHIBITORS
L01EA BCR-ABL tyrosine kinase inhibitors
L01EA03 Nilotinib
D06413 Nilotinib hydrochloride hydrate (JAN) <JP/US>
USP drug classification [BR:br08302]
Antineoplastics
Molecular Target Inhibitors
Nilotinib
D06413 Nilotinib hydrochloride hydrate (JAN)
Therapeutic category of drugs in Japan [BR:br08301]
4 Agents affecting cellular function
42 Antineoplastics
429 Miscellaneous
4291 Other Antitumors
D06413 Nilotinib hydrochloride hydrate (JAN)
Drug groups [BR:br08330]
Antineoplastic
DG01918 Tyrosine kinase inhibitor
DG03161 BCR-ABL inhibitor
DG00716 Nilotinib
D06413 Nilotinib hydrochloride hydrate
Metabolizing enzyme substrate
DG02918 CYP2C8 substrate
DG00716 Nilotinib
D06413 Nilotinib hydrochloride hydrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG00716 Nilotinib
D06413 Nilotinib hydrochloride hydrate
Transporter substrate
DG01665 ABCB1 substrate
DG00716 Nilotinib
D06413 Nilotinib hydrochloride hydrate
Drug classes [BR:br08332]
Antineoplastic
DG03161 BCR-ABL inhibitor
D06413 Nilotinib hydrochloride hydrate
Target-based classification of drugs [BR:br08310]
Protein kinases
Receptor tyrosine kinases (RTK)
PDGFR family
PDGFR
D06413 Nilotinib hydrochloride hydrate (JAN) <JP/US>
KIT (CD117)
D06413 Nilotinib hydrochloride hydrate (JAN) <JP/US>
Non-receptor tyrosine kinases
ABL family
BCR-ABL [HSA_VAR:25v1]
D06413 Nilotinib hydrochloride hydrate (JAN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D06413
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D06413
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D06413
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D06413
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D06413
Drug transporters
D06413
Pharmacogenomic biomarkers [br08341.html]
Somatic variations in targeted cancer therapies
D06413
Polymorphisms and mutations affecting drug response
D06413
Drug groups [BR:br08330]
Antineoplastic
DG01918 Tyrosine kinase inhibitor
DG03161 BCR-ABL inhibitor
DG00716 Nilotinib
Metabolizing enzyme substrate
DG02918 CYP2C8 substrate
DG00716 Nilotinib
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG00716 Nilotinib
Transporter substrate
DG01665 ABCB1 substrate
DG00716 Nilotinib